Gut Dysbiosis at the Intersection of Depression and Addiction: A Microbiota–Gut–Brain–Reward Framework and Digital Precision Behavioural Health Agenda for the United Arab Emirates

Background The microbiota–gut–brain axis provides an emerging framework for understanding neuropsychiatric disorders. Depression and addiction, despite substantial comorbidity, are frequently investigated separately. This review examines whether gut dysbiosis contributes to vulnerability, symptom persistence and recovery through shared inflammatory, endocrine, metabolic and reward-related mechanisms. Methods A structured narrative review was conducted using PubMed/MEDLINE, Scopus, Web of Science and PsycINFO, supplemented by citation searching. Priority was given to systematic reviews, meta-analyses, human cohorts, randomised trials and mechanistic studies. Evidence was evaluated for methodological quality, confounding, replication, biological plausibility and clinical relevance. Results Convergent evidence implicates altered short-chain fatty acid production, intestinal barrier dysfunction, dysregulated tryptophan–kynurenine metabolism, systemic inflammation, hypothalamic–pituitary–adrenal-axis disturbance and altered affective and reward signalling. Human evidence is strongest for major depressive disorder and alcohol use disorder, whereas evidence involving opioids, psychostimulants, cannabis and polysubstance use remains comparatively limited. Dietary interventions, probiotics, prebiotics, synbiotics and faecal microbiota transplantation demonstrate preliminary therapeutic potential. However, methodological heterogeneity, uncertain causality, limited replication and insufficient evidence of sustained benefit prevent routine clinical recommendation. Digital phenotyping, wearable technologies and artificial intelligence may facilitate integration of microbial, metabolic, behavioural and longitudinal clinical information, although prospective validation and demonstrated clinical utility remain limited. Conclusions The proposed Microbiota–Gut–Brain–Reward framework conceptualises dysbiosis as a potentially modifiable contributor rather than an independent cause of depression or addiction. Clinical translation requires longitudinal multi-omic research, harmonised methodologies, mechanistically informed trials and integration with established pharmacological, psychological and social interventions. Digitally enabled precision approaches may support personalised recovery monitoring, provided interpretability, privacy, equity and clinical governance are prioritised. The United Arab Emirates offers opportunities for culturally responsive translational research, although implementation must remain evidence-driven, ethically governed and subject to rigorous prospective evaluation before clinical adoption.

Authors

Institutions

Publication Details

Journal
F1000Research
Published
2026-11-14
DOI
https://doi.org/10.12688/f1000research.192797.1
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Gut Dysbiosis at the Intersection of Depression and Addiction: A Microbiota–Gut–Brain–Reward Framework and Digital Precision Behavioural Health Agenda for the United Arab Emirates

Syed Fahad Javaid, Khalid Awad Al-Kubaisi, Richard Mottershead, Hayder Ameer Jabor et al.
F1000Research
Gut microbiota and health
article

Gut Dysbiosis at the Intersection of Depression and Addiction: A Microbiota–Gut–Brain–Reward Framework and Digital Precision Behavioural Health Agenda for the United Arab Emirates

Syed Fahad Javaid, Khalid Awad Al-Kubaisi, Richard Mottershead, Hayder Ameer Jabor, Nafi Alonaizi, Felix Blaine, Amal Ammar, DAVID FORBES, John Hall, Eric Lott, Hossam Ismail, Aisling Joan Oslizlok, Renz Ocampo
article en

Abstract

Background The microbiota–gut–brain axis provides an emerging framework for understanding neuropsychiatric disorders. Depression and addiction, despite substantial comorbidity, are frequently investigated separately. This review examines whether gut dysbiosis contributes to vulnerability, symptom persistence and recovery through shared inflammatory, endocrine, metabolic and reward-related mechanisms. Methods A structured narrative review was conducted using PubMed/MEDLINE, Scopus, Web of Science and PsycINFO, supplemented by citation searching. Priority was given to systematic reviews, meta-analyses, human cohorts, randomised trials and mechanistic studies. Evidence was evaluated for methodological quality, confounding, replication, biological plausibility and clinical relevance. Results Convergent evidence implicates altered short-chain fatty acid production, intestinal barrier dysfunction, dysregulated tryptophan–kynurenine metabolism, systemic inflammation, hypothalamic–pituitary–adrenal-axis disturbance and altered affective and reward signalling. Human evidence is strongest for major depressive disorder and alcohol use disorder, whereas evidence involving opioids, psychostimulants, cannabis and polysubstance use remains comparatively limited. Dietary interventions, probiotics, prebiotics, synbiotics and faecal microbiota transplantation demonstrate preliminary therapeutic potential. However, methodological heterogeneity, uncertain causality, limited replication and insufficient evidence of sustained benefit prevent routine clinical recommendation. Digital phenotyping, wearable technologies and artificial intelligence may facilitate integration of microbial, metabolic, behavioural and longitudinal clinical information, although prospective validation and demonstrated clinical utility remain limited. Conclusions The proposed Microbiota–Gut–Brain–Reward framework conceptualises dysbiosis as a potentially modifiable contributor rather than an independent cause of depression or addiction. Clinical translation requires longitudinal multi-omic research, harmonised methodologies, mechanistically informed trials and integration with established pharmacological, psychological and social interventions. Digitally enabled precision approaches may support personalised recovery monitoring, provided interpretability, privacy, equity and clinical governance are prioritised. The United Arab Emirates offers opportunities for culturally responsive translational research, although implementation must remain evidence-driven, ethically governed and subject to rigorous prospective evaluation before clinical adoption.

F1000ResearchVol. 15
Suez Canal University (EG), Riyadh Armed Forces Hospital (SA), University of Baghdad (IQ), University of East London (GB), Al Ain University (AE), The University of Melbourne (AU), United Arab Emirates University (AE), American Society of Addiction Medicine (US), Philippine Medical Association (PH), University of Sharjah (AE), University of Al-Qadisiyah (IQ), Dubai Pharmacy College (AE)
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon